Related Experiment Video
Updated: Jun 24, 2026
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases
K Ibler1, T N Dam, R Gniadecki
1Department of Dermatology, University of Copenhagen, Roskilde Hospital, Roskilde, Denmark. kristinaibler@hotmail.com
Background:
Efalizumab is a recombinant humanized murine monoclonal antibody against CD11a, approved for the treatment of plaque psoriasis. However, recent reports suggest that it also may be effective in the treatment of severe atopic dermatitis (AD).
Objective:
To evaluate the clinical effect of efalizumab in AD.
Methods:
A systematic retrospective study of the medical files of patients treated with efalizumab for AD in Danish dermatology departments. Positive outcome was defined as improvement of the disease registered in the patient's file over a period exceeding 6 months.
Results:
Two of eleven patients had a positive outcome. Nine patients stopped treatment due to progression of AD or lack of effect.
Limitations:
Retrospective study.
Conclusions:
Only a minority of patients with severe AD responded to efalizumab treatment in a standard dose.
Related Concept Videos
01:27Acne Infection
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...